For example, comparing the risk of macrovascular CVD outcomes between people with T2DM treated by insulin versus exenatide (a type of GLP-1 RA) in a large ambulatory care dataset, Paul et al [9] found that the risk of incident HF was significantly lower in the exenatide and exenatide+insulin groups compared to the insulin-only group. The gene discussed is GLP1R; the disease is hydrops fetalis.